-
Mashup Score: 0Aduhelm and Alzheimer’s in America - Liberation - 3 year(s) ago
Recent FDA approval for Aduhelm, a treatment for Alzheimer’s disease, has opened the floodgates for conversations about pharmaceutical drug pricing.
Source: LiberationCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
A new study from Milliman investigated the potential financial impact if H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act, was fully implemented.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Adoption of the Lower Drug Costs Now Act May Lead to Billions in Savings: https://t.co/H7oeg7jf1y #drugcosts https://t.co/Qsxfuyf1F2
-
-
Mashup Score: 1
This brief examines how leading federal and state policy options related to changes in Medicaid Drug Rebate Program (MDRP), drug pricing, and payment and management of the Medicaid prescription dru…
Source: KFFCategories: Latest Headlines, PulmonologyTweet-
While #drugcosts were a focus for state Medicaid programs before COVID-19, there may be renewed interest in policy options that would reduce Medicaid Rx drug spending — to address fiscal constraints & meet demands for other pandemic-related spending. https://t.co/fnFpc8xGFR https://t.co/gvN4hILgmW
-
-
Mashup Score: 5
This brief examines how leading federal and state policy options related to changes in Medicaid Drug Rebate Program (MDRP), drug pricing, and payment and management of the Medicaid prescription dru…
Source: KFFCategories: Latest Headlines, PulmonologyTweet-
While #drugcosts were a focus for state Medicaid programs before COVID-19, there may be renewed interest in policy options that would reduce Medicaid Rx drug spending — to address fiscal constraints & meet demands for other pandemic-related spending. https://t.co/fnFpc8xGFR https://t.co/ybMLM5FCcD
-
-
Mashup Score: 3
This brief examines how leading federal and state policy options related to changes in Medicaid Drug Rebate Program (MDRP), drug pricing, and payment and management of the Medicaid prescription dru…
Source: KFFCategories: Latest Headlines, PulmonologyTweet-
While #drugcosts were a focus for state Medicaid programs before COVID-19, there may be renewed interest in policy options that would reduce Medicaid Rx drug spending — to address fiscal constraints & meet demands for other pandemic-related spending. https://t.co/fnFpc8xGFR https://t.co/NhOjj7YjI0
-
-
Mashup Score: 0State drug pricing policies - 4 year(s) ago
US states are pulling various levers to address rising drug prices. An analysis of public databases and interviews with experts show us the areas under focus, the stakeholders that could be affected, and what strategies they should consider.
Source: Deloitte InsightsCategories: Future of Medicine, Latest HeadlinesTweet-
Value-based contracts (VBC) have the potential to help control #drugcosts and improve patient outcomes. Explore the role of VBCs and pricing in our new report. https://t.co/37oPJC6J9u
-
-
Mashup Score: 0Pardon Our Interruption - 4 year(s) ago
As you were browsing www.gastroendonews.com something about your browser made us think you were a bot. There are a few reasons this might happen: You’re a power user moving through this website with super-human speed. You’ve disabled JavaScript in your web browser. A third-party browser plugin, such as…
Source: www.gastroendonews.comCategories: Gastroenterology, Latest HeadlinesTweet-
Even as drug costs skyrocketed over the past decade, the cost of treating pancreatic cancer has declined. https://t.co/wDodBh5Xae @VirginiaMason @DrBobGoldberg @CUPharmacy #pancreaticcancer #drugcosts
-
-
Mashup Score: 0Combining Cancer Medicines for Lower Cost - 4 year(s) ago
What are some ways to lower costs for cancer patients? Read Andrew Schorr’s Power Perspective for some of this thoughts after attending the American Society of Hematology conference.
Source: Patient PowerCategories: Hem/Oncs, Latest HeadlinesTweet-
Here's my latest commentary about the prospect of controlling cancer drug costs and the issues we face: https://t.co/IiIG5CBffF. #cancer #drugcosts #ASH19
-
The @FDA approval of #Aduhelm shocked US #healthcare causing stakeholders to react on #drugprices, #Medicare impacts, #caregivers burdens & challenge of who pays for & benefits from innovation https://t.co/TL8eY2JuSH TY @Medecision hosting my analysis #Aging #Pharma #Drugcosts https://t.co/c32nVZjefP